search

Active clinical trials for "Endometrial Neoplasms"

Results 371-380 of 990

Analysis of miRNA Expression in Endometrial Cancer

Endometrial Cancer

The TCGA project identified four distinct prognostic groups of endometrial carcinoma (EC) based on molecular alterations: (i) the ultramutated subtype that encompasses POLE mutated (POLE) cases; (ii) the hypermutated subtype, characterized by MisMatch Repair deficiency (MMRd); (iii) the copy-number high subtype, with p53 abnormal/mutated features (p53abn); (iv) the copy-number low subtype, known as No Specific Molecular Profile (NSMP). Although the prognostic value of TCGA molecular classification, NSMP carcinomas present a wide variability in molecular alterations and biological aggressiveness. Given that the study aims to evaluate the miRNA expression profile to identify novel potential biomarkers to better stratify the EC patients, taking into account the molecular status

Recruiting5 enrollment criteria

Early Detection of Endometrial Cancer Using Plasma Cell-free DNA Fragmentomics

Endometrial Cancer

The purpose of this study is to enable non-invasive early detection of endometrial cancer in high-risk populations through the establishment of a multimodal machine learning model using plasma cell-free DNA fragmentomics. Plasma cell-free DNA from early stage endometrial cancer patients and healthy individuals will be subjected to whole-genome sequencing. Five different feature types, including Fragment Size Distribution, nucleosome features, SBS Signatures, BreakPoint Motif , and Copy Number Variation will be assessed to generate this model.

Recruiting12 enrollment criteria

Inflammatory Index as a Predictor for Endometrial Cancer: an Observational Study

Endometrial NeoplasmsInflammatory Response

It is a prospective observational trial. Primary goal is identification of an association between alteration of systemic inflammation indices, such as neutrophil-to-lymphocyte ratio (NLR), platelet-t- lymphocyte ratio (PLR), lymphocyte-to-monocyte ratio (MRL) and patients risk classification according to European Guidelines. The population is represented by all women being admitted to the Gynecology Ward, through Emergency, who are affected by endometrial cancer. Participants will undergo surgery, and freely express their consent to participate in the study.

Recruiting8 enrollment criteria

Niraparib in High-grade Endometrial Cancer Trial

Endometrial CancerSerous Adenocarcinoma1 more

The study will investigate the effect of niraparib on tumor tissue in chemotherapy naïve, newly diagnosed, high-grade endometrial cancer patients. Biomarkers of cognate molecular pathways as well as investigational assays will be used to study the antineoplastic effect of the drug.

Not yet recruiting39 enrollment criteria

Hypogastric Plexus Block and Ganglion Impar Block for Cervical and Endometrial Cancer Pain Management...

Cervical CancerEndometrial Cancer

This study compared the efficacy and safety of superior hypogastric plexus block and ganglion impar block procedures on the management of pelvic and perineal cancer pain in patients with cervical and endometrial cancer

Not yet recruiting15 enrollment criteria

Laser Treatment of Genito-urinary Syndrome in Women

Laser-Induced ScarBreast Cancer5 more

Women with genitourinary syndrome of menopause, overactive bladder, with breast or endometrial cancer are randomized to either laser treatment og sham treatment for 3 months. The randomization is stratified for estrogen treatment. The effect is evaluated by questionnaire, histology and microbiology swaps

Not yet recruiting12 enrollment criteria

Alternate Day Fasting After Surgery for Patients Undergoing Chemotherapy

Ovary CancerEndometrial Cancer1 more

Endometrial cancer is the most common gynecologic cancer and ovarian cancer is the most lethal. The management of both advanced cancers is a combination of chemotherapy and surgery. Standard of care chemotherapeutic treatment for uterine and ovarian cancers is toxic and severely disruptive to the patient's quality of life with the potential for devastating short and long-term side effects. The role of fasting and ketogenic diets has been evaluated in a mixed cancer population and previously shown to be safe. There is no data specifically addressing the impact of a fasting diet regimen on side effects of chemotherapy during treatment for ovarian and endometrial cancers in the front-line setting. The information gathered from this study will inform future trials about the role of time-restricted eating and its impact on side-effects associated with chemotherapy as well as its role in improvement of quality of life for women afflicted with these debilitating diseases.

Not yet recruiting16 enrollment criteria

ImpRoving hEalth behaviourS for LIfe After ENdometrial CancEr Trial

Endometrial Cancer

RESILIENCE is 24-week randomized controlled trial that assesses the efficacy of a web-based health platform, combined with online support from healthcare professionals, to enhance waist circumference and other vital health outcomes in endometrial cancer survivors.

Not yet recruiting14 enrollment criteria

FitEx for Endometrial Cancer Survivors: Initial Efficacy

Endometrial CancerObesity3 more

The goal of this clinical trial is to compare physical activity outcomes between endometrial cancer survivors randomized to 1 of 3 conditions: 1) usual care, 2) FitEx, 3) FitEx+yoga. Survivors randomized to FitEx groups will recruit ~3 support team members to complete the intervention with them. The main question[s] it aims to answer are: Do FitEx groups undertake more physical activity than the usual care group? Are there differences in quality of life, self-compassion, flourishing, self-efficacy, social support, habit formation, and fruit /vegetable consumption Participants will: Wear a Fitbit Complete surveys Participate in 30 minute weekly virtual meetings (FitEx groups only) Receive weekly newsletters (FitEx groups only)

Not yet recruiting20 enrollment criteria

Lymphoseek as Lymphoid Tissue Targeting Agent in Patients With Cancer of the Endometrium

Endometrial Cancer

Part of standard treatment for endometrial cancer is to remove one or more groups of lymph nodes (lymph node dissection). Lymph nodes are small, bean-shaped organs located within the body throughout the lymphatic system (the tissues and organs involved in immunity, which aids in the fight against infection and cancer). The purpose of this study is to compare the safety and ability of Lymphoseek and a Vital Blue Dye (tracing agent) to find lymph nodes that may carry cancer from the tumor through the lymphatic system. Lymphoseek will be injected into the tumor on the day before surgery to remove lymph nodes. Vital Blue Dye will be administered during surgery to trace the cancer as well. The surgeon will remove the lymph nodes as part of routine surgery and will keep track of which lymph nodes are identified by Lymphoseek and Vital Blue Dye. These nodes will be sent to another doctor to view them under a microscope and see if the nodes contain cancer cells. The hypothesis is that Lymphoseek can be used safely and will be at least as effective as blue dye in identifying the lymph nodes that may have cancer cells.

Terminated11 enrollment criteria
1...373839...99

Need Help? Contact our team!


We'll reach out to this number within 24 hrs